BPG is committed to discovery and dissemination of knowledge
Welcome to the World Journal of Gastrointestinal Pharmacology and Therapeutics

The World Journal of Gastrointestinal Pharmacology and Therapeutics (WJGPT) is a leading academic journal devoted to reporting the latest, cutting-edge research progress and findings of basic research and clinical practice in the field of gastrointestinal pharmacology and therapeutics.  It was launched on February 6, 2010 and is published trimonthly (4 issues annually) by BPG, the world's leading professional clinical medical journal publishing company.

We encourage pharmacology and therapeutics specialists worldwide to submit manuscripts to the WJGPT describing their original basic or clinical research findings that are of high academic value and which report new diagnostic techniques or summarize their treatment experiences.

The usual times related to all publication processes of the WJGPT are as follows: (1) From manuscript receipt to peer-review: 2-4 weeks; (2) From initial manuscript acceptance, with revisions, to return of the revised manuscript from the authors: 4-5 weeks; (3) From return of the revised manuscript from the authors to final acceptance: 1-2 weeks; (4) From final acceptance to an article in press: 2 days; and (5) From article in press designation to formal release of the electronic version and all online documentation: 2-9 weeks. The WJGPT’s acceptance rate: 49%.  Submit here >>

2017 Published Issues
4 3 2 1
Editors-in-Chief
  • Hugh J Freeman, FACG, FACP, FRCP(C), MD, Professor, (E-mail:hugfree@shaw.ca)Department of Medicine (Gastroenterology) , University of British Columbia, and Senior Active Staff, Vancouver General Hospital and UBC Health Sciences Center Hospital, Vancouver V6T 1W5, British Columbia, Canada
Indexing/Abstracting
PubMed, PubMed Central.
Journal Metrics
There is currently no impact factor.
ISSN
2150-5349 (online)
Case Control Study
Association of miR-146 rs2910164, miR-196a rs11614913, miR-221 rs113054794 and miR-224 rs188519172 polymorphisms with anti-TNF treatment response in a Greek population with Crohn’s disease 
Ioannis Papaconstantinou, Christina Kapizioni, Evangelia Legaki, Elena Xourgia, George Karamanolis, Antonios Gklavas, Maria Gazouli 
World J Gastrointest Pharmacol Ther 8(4):193-200. Published online Nov 6, 2017. doi: 10.4292/wjgpt.v8.i4.193
Protozoan parasites in irritable bowel syndrome: A case-control study 
Khaled A Jadallah, Laila F Nimri, Rola A Ghanem 
World J Gastrointest Pharmacol Ther 8(4):201-207. Published online Nov 6, 2017. doi: 10.4292/wjgpt.v8.i4.201
Letters To The Editor
Fecal microbiota transplantation against irritable bowel syndrome? Rigorous randomized clinical trials are required 
Amin Talebi Bezmin Abadi 
World J Gastrointest Pharmacol Ther 8(4):208-209. Published online Nov 6, 2017. doi: 10.4292/wjgpt.v8.i4.208